Committee Approves Pennycuick Measure to Modernize PA Pharmaceutical Licensing

HARRISBURG - Legislation sponsored by Sen. Tracy Pennycuick (R-24) to make Pennsylvania a more attractive destination for cutting-edge pharmaceutical companies and high-quality jobs was approved by a Senate committee today.

Senate Bill 1206, approved by the Institutional Sustainability and Innovation Committee, would modernize Pennsylvania's licensure process by permitting pharmaceutical manufacturers to apply for state licensure concurrently with the Food and Drug Administration (FDA) approval process.

"Pennsylvania is home to a thriving life sciences sector that develops lifesaving medications and groundbreaking medical technologies," Pennycuick said. "To remain competitive and attract continued investment, we must ensure that our regulatory framework keeps pace with innovation."

Currently, pharmaceutical manufacturers must complete the lengthy FDA approval process before applying for a state license. This requirement can delay introduction of new treatments to the market.

The legislation would not change federal safety standards or approval requirements. Instead, it ensures Pennsylvania is prepared to act once federal approval is granted, reducing unnecessary administrative delays while maintaining strong oversight.

The change would align the commonwealth with several other states that already permit parallel licensure. Senate Bill 1206 now heads toward consideration by the full Senate.

(215) 541-2388